The Market Reports

Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com

Neurodegenerative Drugs-Global Market Insights and Sales Trends 2025

Neurodegenerative Drugs-Global Market Insights and Sales Trends 2025

Publishing Date : Mar, 2025

License Type :
 

Report Code : 1814793

No of Pages : 112

Ask Your Query
Synopsis
Neurodegenerative drugs are medications used to manage and alleviate symptoms associated with neurodegenerative diseases. They may target various aspects of disease progression, such as cognitive function, motor symptoms, and inflammation.
The global Neurodegenerative Drugs market size is expected to reach US$ 173000 million by 2029, growing at a CAGR of 5.9% from 2023 to 2029. The market is mainly driven by the significant applications of Neurodegenerative Drugs in various end use industries. The expanding demands from the Parkinson’s Disease, Huntington Disease, Amyotrophic Lateral Sclerosis and Alzheimer’s Disease, are propelling Neurodegenerative Drugs market. NMDA, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the SSRIs segment is estimated at % CAGR for the next seven-year period.
The market for neurodegenerative drugs is driven by the growing burden of neurodegenerative diseases and the need for effective and disease-modifying treatments. The market's growth is also influenced by ongoing research in neuroscience and the development of novel drug candidates targeting specific neurodegenerative pathways.
Report Objectives
This report provides market insight on the different segments, by manufacturers, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Neurodegenerative Drugs, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Neurodegenerative Drugs market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Neurodegenerative Drugs market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Neurodegenerative Drugs sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Neurodegenerative Drugs covered in this report include Novartis, Pfizer, Merck Serono, Biogen Idec, TEVA, UCB, Boehringer Ingelheim, Sanofi and GlaxoSmithKline, etc.
The global Neurodegenerative Drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Novartis
Pfizer
Merck Serono
Biogen Idec
TEVA
UCB
Boehringer Ingelheim
Sanofi
GlaxoSmithKline
Livzon Pharmaceutical
Haisco Pharmaceutical
Jingxin Pharmaceutical
Dongcheng Biochemicals
Hisun Pharmaceutical
Luye Pharma
Ark Pharmaceutical
Kanghong Pharmaceutical
Huahai Pharmaceutical
BORA PHARMACEUTICALS
Global Neurodegenerative Drugs market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Neurodegenerative Drugs market, Segment by Type:
NMDA
SSRIs
Dopamine Inhibitors
Global Neurodegenerative Drugs market, by Application
Parkinson’s Disease
Huntington Disease
Amyotrophic Lateral Sclerosis
Alzheimer’s Disease
Core Chapters
Chapter One: Introduces the study scope of this report, executive summary of market segments by Type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Two: Detailed analysis of Neurodegenerative Drugs manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Three: Sales, revenue of Neurodegenerative Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter Four: Introduces market segments by Application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Five, Six, Seven, Eight and Nine: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter Ten: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter Eleven: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics. Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Analysis of sales channel, distributors and customers.
Chapter Thirteen: Research Findings and Conclusion.
Index
1 Neurodegenerative Drugs Market Overview
1.1 Neurodegenerative Drugs Product Overview
1.2 Neurodegenerative Drugs Market Segment by Type
1.2.1 NMDA
1.2.2 SSRIs
1.2.3 Dopamine Inhibitors
1.3 Global Neurodegenerative Drugs Market Size by Type
1.3.1 Global Neurodegenerative Drugs Market Size Overview by Type (2018-2029)
1.3.2 Global Neurodegenerative Drugs Historic Market Size Review by Type (2018-2023)
1.3.3 Global Neurodegenerative Drugs Forecasted Market Size by Type (2024-2029)
1.4 Key Regions Market Size Segment by Type
1.4.1 North America Neurodegenerative Drugs Sales Breakdown by Type (2018-2023)
1.4.2 Europe Neurodegenerative Drugs Sales Breakdown by Type (2018-2023)
1.4.3 Asia-Pacific Neurodegenerative Drugs Sales Breakdown by Type (2018-2023)
1.4.4 Latin America Neurodegenerative Drugs Sales Breakdown by Type (2018-2023)
1.4.5 Middle East and Africa Neurodegenerative Drugs Sales Breakdown by Type (2018-2023)
2 Global Neurodegenerative Drugs Market Competition by Company
2.1 Global Top Players by Neurodegenerative Drugs Sales (2018-2023)
2.2 Global Top Players by Neurodegenerative Drugs Revenue (2018-2023)
2.3 Global Top Players by Neurodegenerative Drugs Price (2018-2023)
2.4 Global Top Manufacturers Neurodegenerative Drugs Manufacturing Base Distribution, Sales Area, Product Type
2.5 Neurodegenerative Drugs Market Competitive Situation and Trends
2.5.1 Neurodegenerative Drugs Market Concentration Rate (2018-2023)
2.5.2 Global 5 and 10 Largest Manufacturers by Neurodegenerative Drugs Sales and Revenue in 2022
2.6 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Neurodegenerative Drugs as of 2022)
2.7 Date of Key Manufacturers Enter into Neurodegenerative Drugs Market
2.8 Key Manufacturers Neurodegenerative Drugs Product Offered
2.9 Mergers & Acquisitions, Expansion
3 Neurodegenerative Drugs Status and Outlook by Region
3.1 Global Neurodegenerative Drugs Market Size and CAGR by Region: 2018 VS 2022 VS 2029
3.2 Global Neurodegenerative Drugs Historic Market Size by Region
3.2.1 Global Neurodegenerative Drugs Sales in Volume by Region (2018-2023)
3.2.2 Global Neurodegenerative Drugs Sales in Value by Region (2018-2023)
3.2.3 Global Neurodegenerative Drugs Sales (Volume & Value) Price and Gross Margin (2018-2023)
3.3 Global Neurodegenerative Drugs Forecasted Market Size by Region
3.3.1 Global Neurodegenerative Drugs Sales in Volume by Region (2024-2029)
3.3.2 Global Neurodegenerative Drugs Sales in Value by Region (2024-2029)
3.3.3 Global Neurodegenerative Drugs Sales (Volume & Value), Price and Gross Margin (2024-2029)
4 Global Neurodegenerative Drugs by Application
4.1 Neurodegenerative Drugs Market Segment by Application
4.1.1 Parkinson’s Disease
4.1.2 Huntington Disease
4.1.3 Amyotrophic Lateral Sclerosis
4.1.4 Alzheimer’s Disease
4.2 Global Neurodegenerative Drugs Market Size by Application
4.2.1 Global Neurodegenerative Drugs Market Size Overview by Application (2018-2029)
4.2.2 Global Neurodegenerative Drugs Historic Market Size Review by Application (2018-2023)
4.2.3 Global Neurodegenerative Drugs Forecasted Market Size by Application (2024-2029)
4.3 Key Regions Market Size Segment by Application
4.3.1 North America Neurodegenerative Drugs Sales Breakdown by Application (2018-2023)
4.3.2 Europe Neurodegenerative Drugs Sales Breakdown by Application (2018-2023)
4.3.3 Asia-Pacific Neurodegenerative Drugs Sales Breakdown by Application (2018-2023)
4.3.4 Latin America Neurodegenerative Drugs Sales Breakdown by Application (2018-2023)
4.3.5 Middle East and Africa Neurodegenerative Drugs Sales Breakdown by Application (2018-2023)
5 North America Neurodegenerative Drugs by Country
5.1 North America Neurodegenerative Drugs Historic Market Size by Country
5.1.1 North America Neurodegenerative Drugs Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
5.1.2 North America Neurodegenerative Drugs Sales in Volume by Country (2018-2023)
5.1.3 North America Neurodegenerative Drugs Sales in Value by Country (2018-2023)
5.2 North America Neurodegenerative Drugs Forecasted Market Size by Country
5.2.1 North America Neurodegenerative Drugs Sales in Volume by Country (2024-2029)
5.2.2 North America Neurodegenerative Drugs Sales in Value by Country (2024-2029)
6 Europe Neurodegenerative Drugs by Country
6.1 Europe Neurodegenerative Drugs Historic Market Size by Country
6.1.1 Europe Neurodegenerative Drugs Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
6.1.2 Europe Neurodegenerative Drugs Sales in Volume by Country (2018-2023)
6.1.3 Europe Neurodegenerative Drugs Sales in Value by Country (2018-2023)
6.2 Europe Neurodegenerative Drugs Forecasted Market Size by Country
6.2.1 Europe Neurodegenerative Drugs Sales in Volume by Country (2024-2029)
6.2.2 Europe Neurodegenerative Drugs Sales in Value by Country (2024-2029)
7 Asia-Pacific Neurodegenerative Drugs by Region
7.1 Asia-Pacific Neurodegenerative Drugs Historic Market Size by Region
7.1.1 Asia-Pacific Neurodegenerative Drugs Market Size Growth Rate (CAGR) by Region: 2018 VS 2022 VS 2029
7.1.2 Asia-Pacific Neurodegenerative Drugs Sales in Volume by Region (2018-2023)
7.1.3 Asia-Pacific Neurodegenerative Drugs Sales in Value by Region (2018-2023)
7.2 Asia-Pacific Neurodegenerative Drugs Forecasted Market Size by Region
7.2.1 Asia-Pacific Neurodegenerative Drugs Sales in Volume by Region (2024-2029)
7.2.2 Asia-Pacific Neurodegenerative Drugs Sales in Value by Region (2024-2029)
8 Latin America Neurodegenerative Drugs by Country
8.1 Latin America Neurodegenerative Drugs Historic Market Size by Country
8.1.1 Latin America Neurodegenerative Drugs Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
8.1.2 Latin America Neurodegenerative Drugs Sales in Volume by Country (2018-2023)
8.1.3 Latin America Neurodegenerative Drugs Sales in Value by Country (2018-2023)
8.2 Latin America Neurodegenerative Drugs Forecasted Market Size by Country
8.2.1 Latin America Neurodegenerative Drugs Sales in Volume by Country (2024-2029)
8.2.2 Latin America Neurodegenerative Drugs Sales in Value by Country (2024-2029)
9 Middle East and Africa Neurodegenerative Drugs by Country
9.1 Middle East and Africa Neurodegenerative Drugs Historic Market Size by Country
9.1.1 Middle East and Africa Neurodegenerative Drugs Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
9.1.2 Middle East and Africa Neurodegenerative Drugs Sales in Volume by Country (2018-2023)
9.1.3 Middle East and Africa Neurodegenerative Drugs Sales in Value by Country (2018-2023)
9.2 Middle East and Africa Neurodegenerative Drugs Forecasted Market Size by Country
9.2.1 Middle East and Africa Neurodegenerative Drugs Sales in Volume by Country (2024-2029)
9.2.2 Middle East and Africa Neurodegenerative Drugs Sales in Value by Country (2024-2029)
10 Company Profiles
10.1 Novartis
10.1.1 Novartis Company Information
10.1.2 Novartis Introduction and Business Overview
10.1.3 Novartis Neurodegenerative Drugs Sales, Revenue and Gross Margin (2018-2023)
10.1.4 Novartis Neurodegenerative Drugs Products Offered
10.1.5 Novartis Recent Development
10.2 Pfizer
10.2.1 Pfizer Company Information
10.2.2 Pfizer Introduction and Business Overview
10.2.3 Pfizer Neurodegenerative Drugs Sales, Revenue and Gross Margin (2018-2023)
10.2.4 Pfizer Neurodegenerative Drugs Products Offered
10.2.5 Pfizer Recent Development
10.3 Merck Serono
10.3.1 Merck Serono Company Information
10.3.2 Merck Serono Introduction and Business Overview
10.3.3 Merck Serono Neurodegenerative Drugs Sales, Revenue and Gross Margin (2018-2023)
10.3.4 Merck Serono Neurodegenerative Drugs Products Offered
10.3.5 Merck Serono Recent Development
10.4 Biogen Idec
10.4.1 Biogen Idec Company Information
10.4.2 Biogen Idec Introduction and Business Overview
10.4.3 Biogen Idec Neurodegenerative Drugs Sales, Revenue and Gross Margin (2018-2023)
10.4.4 Biogen Idec Neurodegenerative Drugs Products Offered
10.4.5 Biogen Idec Recent Development
10.5 TEVA
10.5.1 TEVA Company Information
10.5.2 TEVA Introduction and Business Overview
10.5.3 TEVA Neurodegenerative Drugs Sales, Revenue and Gross Margin (2018-2023)
10.5.4 TEVA Neurodegenerative Drugs Products Offered
10.5.5 TEVA Recent Development
10.6 UCB
10.6.1 UCB Company Information
10.6.2 UCB Introduction and Business Overview
10.6.3 UCB Neurodegenerative Drugs Sales, Revenue and Gross Margin (2018-2023)
10.6.4 UCB Neurodegenerative Drugs Products Offered
10.6.5 UCB Recent Development
10.7 Boehringer Ingelheim
10.7.1 Boehringer Ingelheim Company Information
10.7.2 Boehringer Ingelheim Introduction and Business Overview
10.7.3 Boehringer Ingelheim Neurodegenerative Drugs Sales, Revenue and Gross Margin (2018-2023)
10.7.4 Boehringer Ingelheim Neurodegenerative Drugs Products Offered
10.7.5 Boehringer Ingelheim Recent Development
10.8 Sanofi
10.8.1 Sanofi Company Information
10.8.2 Sanofi Introduction and Business Overview
10.8.3 Sanofi Neurodegenerative Drugs Sales, Revenue and Gross Margin (2018-2023)
10.8.4 Sanofi Neurodegenerative Drugs Products Offered
10.8.5 Sanofi Recent Development
10.9 GlaxoSmithKline
10.9.1 GlaxoSmithKline Company Information
10.9.2 GlaxoSmithKline Introduction and Business Overview
10.9.3 GlaxoSmithKline Neurodegenerative Drugs Sales, Revenue and Gross Margin (2018-2023)
10.9.4 GlaxoSmithKline Neurodegenerative Drugs Products Offered
10.9.5 GlaxoSmithKline Recent Development
10.10 Livzon Pharmaceutical
10.10.1 Livzon Pharmaceutical Company Information
10.10.2 Livzon Pharmaceutical Introduction and Business Overview
10.10.3 Livzon Pharmaceutical Neurodegenerative Drugs Sales, Revenue and Gross Margin (2018-2023)
10.10.4 Livzon Pharmaceutical Neurodegenerative Drugs Products Offered
10.10.5 Livzon Pharmaceutical Recent Development
10.11 Haisco Pharmaceutical
10.11.1 Haisco Pharmaceutical Company Information
10.11.2 Haisco Pharmaceutical Introduction and Business Overview
10.11.3 Haisco Pharmaceutical Neurodegenerative Drugs Sales, Revenue and Gross Margin (2018-2023)
10.11.4 Haisco Pharmaceutical Neurodegenerative Drugs Products Offered
10.11.5 Haisco Pharmaceutical Recent Development
10.12 Jingxin Pharmaceutical
10.12.1 Jingxin Pharmaceutical Company Information
10.12.2 Jingxin Pharmaceutical Introduction and Business Overview
10.12.3 Jingxin Pharmaceutical Neurodegenerative Drugs Sales, Revenue and Gross Margin (2018-2023)
10.12.4 Jingxin Pharmaceutical Neurodegenerative Drugs Products Offered
10.12.5 Jingxin Pharmaceutical Recent Development
10.13 Dongcheng Biochemicals
10.13.1 Dongcheng Biochemicals Company Information
10.13.2 Dongcheng Biochemicals Introduction and Business Overview
10.13.3 Dongcheng Biochemicals Neurodegenerative Drugs Sales, Revenue and Gross Margin (2018-2023)
10.13.4 Dongcheng Biochemicals Neurodegenerative Drugs Products Offered
10.13.5 Dongcheng Biochemicals Recent Development
10.14 Hisun Pharmaceutical
10.14.1 Hisun Pharmaceutical Company Information
10.14.2 Hisun Pharmaceutical Introduction and Business Overview
10.14.3 Hisun Pharmaceutical Neurodegenerative Drugs Sales, Revenue and Gross Margin (2018-2023)
10.14.4 Hisun Pharmaceutical Neurodegenerative Drugs Products Offered
10.14.5 Hisun Pharmaceutical Recent Development
10.15 Luye Pharma
10.15.1 Luye Pharma Company Information
10.15.2 Luye Pharma Introduction and Business Overview
10.15.3 Luye Pharma Neurodegenerative Drugs Sales, Revenue and Gross Margin (2018-2023)
10.15.4 Luye Pharma Neurodegenerative Drugs Products Offered
10.15.5 Luye Pharma Recent Development
10.16 Ark Pharmaceutical
10.16.1 Ark Pharmaceutical Company Information
10.16.2 Ark Pharmaceutical Introduction and Business Overview
10.16.3 Ark Pharmaceutical Neurodegenerative Drugs Sales, Revenue and Gross Margin (2018-2023)
10.16.4 Ark Pharmaceutical Neurodegenerative Drugs Products Offered
10.16.5 Ark Pharmaceutical Recent Development
10.17 Kanghong Pharmaceutical
10.17.1 Kanghong Pharmaceutical Company Information
10.17.2 Kanghong Pharmaceutical Introduction and Business Overview
10.17.3 Kanghong Pharmaceutical Neurodegenerative Drugs Sales, Revenue and Gross Margin (2018-2023)
10.17.4 Kanghong Pharmaceutical Neurodegenerative Drugs Products Offered
10.17.5 Kanghong Pharmaceutical Recent Development
10.18 Huahai Pharmaceutical
10.18.1 Huahai Pharmaceutical Company Information
10.18.2 Huahai Pharmaceutical Introduction and Business Overview
10.18.3 Huahai Pharmaceutical Neurodegenerative Drugs Sales, Revenue and Gross Margin (2018-2023)
10.18.4 Huahai Pharmaceutical Neurodegenerative Drugs Products Offered
10.18.5 Huahai Pharmaceutical Recent Development
10.19 BORA PHARMACEUTICALS
10.19.1 BORA PHARMACEUTICALS Company Information
10.19.2 BORA PHARMACEUTICALS Introduction and Business Overview
10.19.3 BORA PHARMACEUTICALS Neurodegenerative Drugs Sales, Revenue and Gross Margin (2018-2023)
10.19.4 BORA PHARMACEUTICALS Neurodegenerative Drugs Products Offered
10.19.5 BORA PHARMACEUTICALS Recent Development
11 Upstream, Opportunities, Challenges, Risks and Influences Factors Analysis
11.1 Neurodegenerative Drugs Key Raw Materials
11.1.1 Key Raw Materials
11.1.2 Key Raw Materials Price
11.1.3 Raw Materials Key Suppliers
11.2 Manufacturing Cost Structure
11.2.1 Raw Materials
11.2.2 Labor Cost
11.2.3 Manufacturing Expenses
11.3 Neurodegenerative Drugs Industrial Chain Analysis
11.4 Neurodegenerative Drugs Market Dynamics
11.4.1 Neurodegenerative Drugs Industry Trends
11.4.2 Neurodegenerative Drugs Market Drivers
11.4.3 Neurodegenerative Drugs Market Challenges
11.4.4 Neurodegenerative Drugs Market Restraints
12 Market Strategy Analysis, Distributors
12.1 Sales Channel
12.2 Neurodegenerative Drugs Distributors
12.3 Neurodegenerative Drugs Downstream Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details
14.3 Disclaimer

Published By : QY Research

Why ‘The Market Reports’

In Business: Pre Sales Support: Post Sales Support: Turn Around Time: Clients Served: Clients Assisted: Client Types: Payment: Partners with: Number of reports: Custom Research: Report Availability: Report Delivery Format: Security:

Payments Accepted From

Connect with us at

Complete Secure Website

SiteLock